Cargando…
PD-L1 Status in Tenosynovial Giant Cell Tumors
Background and Objectives: Tenosynovial giant cell tumors (TSGCTs) are benign soft tissue tumors that are divided into localized- and diffuse-type tumors, according to the World Health Organization classification of soft tissue tumours. The diffuse-type TSGCT sometimes behave aggressively and poses...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501118/ https://www.ncbi.nlm.nih.gov/pubmed/36143947 http://dx.doi.org/10.3390/medicina58091270 |
_version_ | 1784795395069575168 |
---|---|
author | Zenginkinet, Tulay Faruq, Abdullahi Umar Toksoz Yildirim, Ayse Nur Iyetin, Yusuf Ozturan, Burak Okay, Erhan Celik, Aykut Ozkan, Korhan Akyurek, Muhlik |
author_facet | Zenginkinet, Tulay Faruq, Abdullahi Umar Toksoz Yildirim, Ayse Nur Iyetin, Yusuf Ozturan, Burak Okay, Erhan Celik, Aykut Ozkan, Korhan Akyurek, Muhlik |
author_sort | Zenginkinet, Tulay |
collection | PubMed |
description | Background and Objectives: Tenosynovial giant cell tumors (TSGCTs) are benign soft tissue tumors that are divided into localized- and diffuse-type tumors, according to the World Health Organization classification of soft tissue tumours. The diffuse-type TSGCT sometimes behave aggressively and poses treatment challenges especially in patients with neurovascular involvement. Symptomatic patients who are not good candidates for surgery due to high morbidity risk may benefit from medical therapy. Objectives: Drugs that target programmed death ligand 1 (PD-L1) are among a new generation of medical therapy options, which, recently, have been explored and have displayed promising results in various cancer types; therefore, we aimed to investigate the PD-L1 status of TSGCTs as a possible therapeutic target. Materials and Methods: We assessed the PD-L1 status of 20 patients (15 men and 5 women, median age = 39 years) that had been diagnosed with TSGCTs in a single institution, between 2018 and 2020. The patients had localized- (n = 7) and diffuse-type (n = 13) TSGCTs. Formalin-fixed paraffin-embedded (FFPE) blocks were retrospectively retrieved from the pathology department. An immunohistochemical analysis was performed in sections of 3 micron thickness from these blocks. Results: Seventy-five percent of our patients with TSGCTs were immunopositive to PD-L1 staining. Conclusions: Taking into consideration the high positivity rate of PD-L1 staining in TSGCTs, PD-L1 blockage may be used as a valuable medical treatment for TSGCTs; however, further studies are needed. |
format | Online Article Text |
id | pubmed-9501118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95011182022-09-24 PD-L1 Status in Tenosynovial Giant Cell Tumors Zenginkinet, Tulay Faruq, Abdullahi Umar Toksoz Yildirim, Ayse Nur Iyetin, Yusuf Ozturan, Burak Okay, Erhan Celik, Aykut Ozkan, Korhan Akyurek, Muhlik Medicina (Kaunas) Article Background and Objectives: Tenosynovial giant cell tumors (TSGCTs) are benign soft tissue tumors that are divided into localized- and diffuse-type tumors, according to the World Health Organization classification of soft tissue tumours. The diffuse-type TSGCT sometimes behave aggressively and poses treatment challenges especially in patients with neurovascular involvement. Symptomatic patients who are not good candidates for surgery due to high morbidity risk may benefit from medical therapy. Objectives: Drugs that target programmed death ligand 1 (PD-L1) are among a new generation of medical therapy options, which, recently, have been explored and have displayed promising results in various cancer types; therefore, we aimed to investigate the PD-L1 status of TSGCTs as a possible therapeutic target. Materials and Methods: We assessed the PD-L1 status of 20 patients (15 men and 5 women, median age = 39 years) that had been diagnosed with TSGCTs in a single institution, between 2018 and 2020. The patients had localized- (n = 7) and diffuse-type (n = 13) TSGCTs. Formalin-fixed paraffin-embedded (FFPE) blocks were retrospectively retrieved from the pathology department. An immunohistochemical analysis was performed in sections of 3 micron thickness from these blocks. Results: Seventy-five percent of our patients with TSGCTs were immunopositive to PD-L1 staining. Conclusions: Taking into consideration the high positivity rate of PD-L1 staining in TSGCTs, PD-L1 blockage may be used as a valuable medical treatment for TSGCTs; however, further studies are needed. MDPI 2022-09-13 /pmc/articles/PMC9501118/ /pubmed/36143947 http://dx.doi.org/10.3390/medicina58091270 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zenginkinet, Tulay Faruq, Abdullahi Umar Toksoz Yildirim, Ayse Nur Iyetin, Yusuf Ozturan, Burak Okay, Erhan Celik, Aykut Ozkan, Korhan Akyurek, Muhlik PD-L1 Status in Tenosynovial Giant Cell Tumors |
title | PD-L1 Status in Tenosynovial Giant Cell Tumors |
title_full | PD-L1 Status in Tenosynovial Giant Cell Tumors |
title_fullStr | PD-L1 Status in Tenosynovial Giant Cell Tumors |
title_full_unstemmed | PD-L1 Status in Tenosynovial Giant Cell Tumors |
title_short | PD-L1 Status in Tenosynovial Giant Cell Tumors |
title_sort | pd-l1 status in tenosynovial giant cell tumors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501118/ https://www.ncbi.nlm.nih.gov/pubmed/36143947 http://dx.doi.org/10.3390/medicina58091270 |
work_keys_str_mv | AT zenginkinettulay pdl1statusintenosynovialgiantcelltumors AT faruqabdullahiumar pdl1statusintenosynovialgiantcelltumors AT toksozyildirimaysenur pdl1statusintenosynovialgiantcelltumors AT iyetinyusuf pdl1statusintenosynovialgiantcelltumors AT ozturanburak pdl1statusintenosynovialgiantcelltumors AT okayerhan pdl1statusintenosynovialgiantcelltumors AT celikaykut pdl1statusintenosynovialgiantcelltumors AT ozkankorhan pdl1statusintenosynovialgiantcelltumors AT akyurekmuhlik pdl1statusintenosynovialgiantcelltumors |